Biogen wanted to manufacture enough Aducanumab to treat one million Alzheimer’s patients worldwide—but that required increasing production, improving yield, and reducing costs. The company used AVEVA PI System to enable real-time visibility and contextualized insights on the plant floor. With real-time review by exception, teams can now make adjustments before the batch moves on to the next step, allowing the company to reduce costs, increase yield, and expand production efforts.
“Our goal with AVEVA PI System is to turn it into a central point of information driving some of our really key, data-rich applications and work processes.”
Tim Alosi, Head of Global Digital Analytics Team, Biogen
Goals
- Manufacture enough Aducanumab to treat one million patients
- Reduce costs from $10,000 to $100-150 per gram
- Predict batch quality to make changes in real time
Challenges
- Lacked visibility to correct issues in real-time
- Must adhere to stringent regulatory requirements
- Must adhere to stringent regulatory requirements
Solution
Results
- Implemented real-time review by exception
- Reduced manufacturing costs and increased yield
- Ability to adjust manufacturing processes in real time
Related Success Stories
Stay in the know: Keep up to date on the latest happenings around the industry.
